![Shigeyuki Nishinaka](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shigeyuki Nishinaka
Direktor/Vorstandsmitglied bei MYOVANT SCIENCES LTD.
Aktive Positionen von Shigeyuki Nishinaka
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | 01.01.2009 | - |
Direktor/Vorstandsmitglied | 01.04.2022 | 25.06.2024 | |
UROVANT SCIENCES LTD. | Direktor/Vorstandsmitglied | 27.12.2019 | - |
Independent Dir/Board Member | 27.12.2019 | - | |
MYOVANT SCIENCES LTD. | Direktor/Vorstandsmitglied | 22.10.2022 | - |
Sumitovant Biopharma, Inc.
![]() Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - | - |
Meltin MMI KK
![]() Meltin MMI KK Medical SpecialtiesHealth Technology Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan. | Direktor/Vorstandsmitglied | - | - |
Sumitomo Pharma America, Inc.
![]() Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Direktor/Vorstandsmitglied | - | - |
Urovant Sciences, Inc.
![]() Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Direktor/Vorstandsmitglied | 01.12.2019 | - |
Karriereverlauf von Shigeyuki Nishinaka
Ehemalige bekannte Positionen von Shigeyuki Nishinaka
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Financial Services Agency | Corporate Officer/Principal | 01.01.2001 | - |
Ausbildung von Shigeyuki Nishinaka
Hiroshima University | Doctorate Degree |
Statistik
International
Japan | 5 |
Vereinigte Staaten | 4 |
Vereinigtes Königreich | 3 |
Operativ
Director/Board Member | 7 |
Corporate Officer/Principal | 2 |
Independent Dir/Board Member | 1 |
Sektoral
Health Technology | 8 |
Government | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SUMITOMO PHARMA CO., LTD. | Health Technology |
Private Unternehmen | 7 |
---|---|
Financial Services Agency | Government |
Urovant Sciences Ltd.
![]() Urovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Sumitovant Biopharma, Inc.
![]() Sumitovant Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Sumitovant Biopharma, Inc. provides biotechnology services. It offers oncology, gene therapy, rare, pulmonary, urological disease, digital innovation and novel platforms. The company is headquartered in New York, NY. | Health Technology |
Meltin MMI KK
![]() Meltin MMI KK Medical SpecialtiesHealth Technology Meltin MMI KK develops bio-signal interface technologies. It offers biosignal processing and cable-driven ststems. The company was founded by Sumio Ito, Masahoro Kasuya and Tatsuya Seki and is headquartered in Tokyo, Japan. | Health Technology |
Sumitomo Pharma America, Inc.
![]() Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 1984 and is headquartered in Marlborough, MA. | Health Technology |
Urovant Sciences, Inc.
![]() Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Health Technology |
Myovant Sciences Ltd.
![]() Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Shigeyuki Nishinaka
- Erfahrung